Part IThe Story
Good Afternoon and Good Morning
On April 26, 2010, Ge Li walked into a conference room at the headquarters of Charles River Laboratories in Wilmington, Massachusetts, to sell the company he had spent a decade building. Three senior Charles River executives sat across the table. Bankers and fund managers listened by speakerphone. By one Chinese account of the meeting, introductions were brief and the business summaries were briefer, because everyone already knew why they were there. The price was $1.6 billion. If the deal closed, a Shanghai contract chemistry shop that had started with four founders and a single 7,000-square-foot laboratory would become part of what one retrospective called the world's largest contract research organization, and a Chinese company would sit, for the first time, near the center of a transaction that size.
That same day a letter went out under Li's name to his employees. It opened with a salutation that reads, at first, like a typo, and on a second reading like a portrait of the whole enterprise: "Good afternoon and good morning, WuXi AppTec colleagues."
Afternoon in Massachusetts. Morning, already, in Shanghai. Li had built a company that lived on both sides of the international date line, so even a greeting had to be in two time zones. Six years earlier he had told a reporter that his chemists in Shanghai routinely stayed at the bench until 10 or 11 at night so they could talk to clients in New Jersey and California during American office hours. The company's working day was arranged around someone else's clock. Its founder carried an American passport and kept his office at 288 Fute Zhong Road in the Waigaoqiao Free Trade Zone. The business model asked the world's drug companies to trust a Chinese laboratory with their most valuable secrets, the unpatented molecules that might someday be worth billions. That trust was the product.
The deal died. Charles River's shareholders balked. Three large holders, in the same Chinese account, judged a 38 percent premium excessive for a Chinese company, and the phrase hangs in the retelling more heavily than its authors may have intended. On July 30, 2010, Li published an open letter blaming "short-term financial concerns" and regretting that the collapse would slow WuXi's evolution into a broader research organization. Then he went back to Shanghai and built the integrated capability himself. In 2015 he took the company private at roughly $3.3 billion, about double the price Charles River had refused. Three years later he relisted it at home, in Shanghai and Hong Kong. By 2021 the "WuXi Group," meaning the original company plus the biologics and cell-therapy businesses it had spun off, was approaching a combined market capitalization of a trillion renminbi.
Sixteen years after Wilmington, the United States Department of Defense placed WuXi AppTec on its list of "Chinese military companies" operating in America. A law written with WuXi's name in it had been signed six months before that. The man who had greeted his staff in two time zones at once now found that each time zone had its own view of who he was.
None of the people in that 2010 conference room could have guessed that ending. Li, though, had been preparing for some version of it all his life. That doesn't mean he foresaw it. It means he had always lived in the gap between two places and treated the gap as a place to do business. His whole career has been an argument that a laboratory can be neutral ground. The last few years have been an argument back.
By the Numbers
The Shovel Seller
7,000 sq ftWuXi's single laboratory at founding, in 2000
$1.6BPrice Charles River agreed to pay in 2010, before its shareholders balked
20%Drop in WuXi's NYSE shares after its March 2015 earnings report
$3.3BValue of the 2015 take-private transaction
39,000Employees reported as of 2025
6,000Customers reported as of 2025
$10BForbes estimate of Li's net worth, 2022
An R&D Mall in a Free Trade Zone
In the summer of 2004, Jean-François Tremblay, a correspondent for Chemical & Engineering News, the trade magazine of the American Chemical Society, toured WuXi PharmaTech's rented laboratories in Waigaoqiao. He covered Asian chemistry for years, and WuXi would become a recurring assignment: he profiled it in 2004 and again in 2016, and his magazine later named it Company of the Year for 2018. In effect he was the company's long-running Western witness. In 2004 he called the labs "an R&D mall of the world's most famous drug companies."
It is a good phrase, and an exact one. One room ran projects for Sumitomo Chemical. Another handled Merck & Co. Scientists in the next room worked for a third major drugmaker whose name the article withheld. In a conference hall down the corridor, a researcher from Eli Lilly was giving a seminar. Tremblay also noticed details nobody would bother to stage for a reporter, the kind that tell you how a place runs. Most of the chemists wore safety glasses, which he called "a rare sight in China." The hallways had emergency showers.
Those glasses and showers did more selling than any brochure. A pharmaceutical executive deciding whether to send compounds to a stranger in Shanghai had to ask whether the stranger could do the chemistry, and a credential could answer that. The harder question was whether the work would be done the way it would be done in New Jersey, where the procedures were familiar and the lawyers had leverage. The eyewear answered that one. WuXi was turning the outward habits of Western lab culture into a sales argument.
Li was 37. He had come home, by his own count, after 12 years in the United States. The company's founding is dated to December 2000 in corporate histories and to 2001 in his telling to Tremblay, and the gap probably reflects the difference between incorporating a company and actually moving to run it. He had founded it with three partners. Xiaozhong Liu was a mathematician and physicist who became executive vice president, the kind of numerate generalist every early-stage operation needs to keep the scientists honest about money. Tao Lin ran internal operations. Zhaohui Zhang handled domestic marketing, which turned out to be the job with the least to do. Li had expected WuXi to serve Chinese drug companies. Instead, he told Tremblay, it was "immediately easier to sign up foreign customers than Chinese ones," as though foreign drugmakers had been waiting a long time for someone to let them send work to China.
The company had also learned to use geography. It had invested $12 million in the free trade zone, $5 million of it in imported instruments. Inside the zone, Li explained, instruments and spare parts came in tax-free, which saved about $1.5 million. Lab chemicals ordered from abroad arrived in about a week, so a missing reagent no longer stalled a project for a month. For a contract research business, where the customer is paying for speed, that week was the margin.
About two hours away, at the other end of Shanghai in Jinshan, WuXi had put another $6 million into a plant certified under current Good Manufacturing Practices. It was built to make active pharmaceutical ingredients in kilogram or ton quantities, enough for a client to start toxicology studies or clinical trials on material WuXi had first synthesized in milligrams. Zoning rules put it in a different district. Strategy put it downstream. WuXi was following its customers' molecules down the development pipeline before the customers had asked it to.
Sales had tripled in the 2002–03 fiscal year, and Li expected them to double again. He employed more than 200 scientists and expected 500 within a year or two. American competitors who had doubted WuXi, he said, were now trying to work with it. Read today, the most revealing line in the article may be Tremblay's opening: "The past three years have been a dizzying ride for Ge Li." It was meant as a compliment and was one, but it also left something out. Fifteen years later Li would be asked to explain, in Washington's terms, which way he faced, and nobody had asked him that in 2004.
Combinatorial Libraries
He was born in Beijing in January 1967. A Chinese biographical site gives his ancestral home as Pingyang County in Wenzhou, the coastal city whose merchants are famous across China for frugality and for going wherever trade leads them, and with a local paper's taste for rankings it calls him Wenzhou's richest man, a superlative from a city he was not born in. He attended the Affiliated High School of Peking University and then the university itself, graduating in chemistry in 1989. That same year he left for New York.
The year needs no annotation here. In the sources available, Li has never annotated it either.
At Columbia he earned a doctorate in organic chemistry in 1994. The department was distinguished. Its own histories list Gilbert Stork, Ronald Breslow, Koji Nakanishi and W. Clark Still, and Nakanishi and Still between them advised Li's dissertation and that of the classmate he would marry. The research, as summarized in one profile, concerned synthetic molecular receptors and combinatorial libraries for biomolecular recognition. Put plainly: build many related molecules at once, test them all, and let the data say which ones bind. You don't guess the winner. You make enough candidates that a winner can appear.
He was already working before the degree was conferred. In 1993 he became one of the founding scientists at Pharmacopeia, Inc., in Princeton, New Jersey, then a leading combinatorial chemistry company, and over seven years he held "various scientific and management leadership roles" and co-developed three compounds that reached clinical evaluation. By 1999 he was head of research.
The combinatorial method is worth dwelling on, because it is a cast of mind and Li never dropped it. It assumes nobody can predict which molecule will work, so the sensible response is to build the capacity to test everything quickly and cheaply. Seventeen years after leaving Pharmacopeia, Tremblay asked him whether WuXi, having watched thousands of drug programs pass through its labs, had special insight into which ones would succeed. His answer was a combinatorial chemist's answer:
"We don't have a crystal ball to know that this or that program will be successful. If everyone starts focusing on one target, it doesn't mean that this target will work."
Investors kept hearing modesty or evasion in that. It may have been neither. Li had been trained to distrust predictions and to build libraries. WuXi became a library in that sense: an enormous, fast, cheap capacity for chemistry, open to anyone with a hypothesis, indifferent to which hypothesis turned out right. In combinatorial chemistry the library has no stake in which compound wins. That indifference became Li's business model, and over the next decade it would become his political position too, and he would find out it was harder to hold there.
The Accidental Entrepreneur
On April 20, 2012, Li did two things that, read together, describe the double life of a founder of a foreign-listed Chinese company. He signed the Sarbanes-Oxley certifications for WuXi PharmaTech's annual report on Form 20-F, attesting under federal law that "this report does not contain any untrue statement of a material fact." And Peking University's School of Life Sciences dated the listing for a career lecture he gave to students on its Beijing campus. The lecture was titled Being an Accidental Entrepreneur.
The accident was a trip that failed. In 1999 Pharmacopeia sent its head of research to China to set up a research joint venture. The venture never happened. But Li saw what the trip had shown him: China had no pharmaceutical contract research organization, and it had a great many chemists. In Tremblay's later summary he was "motivated by the visit," left his job, went back, and started his own firm.
The mission failed and the reconnaissance succeeded. That pattern recurs. Pharmacopeia wanted a Chinese partner and couldn't find one, so Li became the partner nobody had built yet. Charles River wanted to buy the integrated platform and its shareholders refused, so Li built the platform without them. Each time someone declined, Li made the thing they had declined.
His word for it is "accidental," but the follow-through was not. By August 2005 he was sitting on a panel organized by the American Chamber of Commerce in China, next to Pfizer China's chief executive and Nike's chief representative, under the title Intellectual Property (IP) Protection in China: Where Are We Headed? The company's own press release paraphrased his position bluntly. Without dramatic improvements in intellectual property protection in China, he said, there would be no R&D service industry, "and no WuXi PharmaTech would exist today." Without strong protection, he warned, international drugmakers would hesitate to bring new medicines to China.
Most founders don't say this kind of thing out loud. Li said in public that his company existed only because Beijing had decided to enforce foreigners' patents, which made WuXi's survival depend on a policy it did not control. Western clients would send molecules to Shanghai only if they believed the molecules would come back with their ownership intact. Every Merck room in Waigaoqiao rested on that belief, and the belief rested on the state.
A Chinese retrospective on the industry uses a phrase that Li has never used about himself and that fits him better than "accidental": WuXi is a shovel seller. In a gold rush, miners pay for shovels whether or not they find gold. Drug companies pay for chemistry whether or not the drug works. The shovel seller doesn't need a crystal ball. It needs to be trusted with other people's mines.
A Fifth Founder
The 2004 C&EN article names three partners besides Li, and Ning Zhao is not among them. Later accounts put her at the center: the English-language encyclopedia entries say Li co-founded WuXi with his wife, and Chinese profiles describe the couple together as top students who built a pharmaceutical giant. I can't settle the discrepancy from the record, and it may not need settling. Many founding stories list the names on the incorporation papers and leave out the person at the kitchen table.
Zhao had been Li's classmate at Peking University and then a fellow doctoral student in Columbia's chemistry department, where she finished a year after him, in 1995. James Valentini, who taught them both and later became dean of Columbia College, said in 2020 that he had known "Ge and Ning ever since they came to Columbia Chemistry as graduate students." At WuXi she was a board member and senior vice president and became global head of human resources. In a company whose basic promise to clients was that skilled chemists would work late and follow the rules, the person in charge of people was in charge of the product.
She died on May 16, 2023, at 56, after what Forbes described as a twenty-year battle with cancer.
Twenty years means the illness started around 2003, in the company's third or fourth year, before the NYSE listing and before Tremblay's first visit. It means the woman responsible for hiring and keeping WuXi's workforce did that job while ill for almost the entire life of the firm. Neither of them talked about it publicly, at least in any record available to me, and the silence fits everything else about how they lived. What they left was a list of gifts. In 2018 they gave 100 million renminbi to Peking University to establish the Li Ge–Zhao Ning Education Fund, and the university named them honorary trustees. On July 28, 2020, they gave Columbia $21.5 million: two endowed chemistry professorships with laboratory start-up funds, an endowed graduate fellowship, and an endowed scholarship for undergraduates concentrating in chemistry. Columbia called it one of the largest gifts to the sciences on its Morningside campus in the university's history. In May 2021 they gave $20 million to Memorial Sloan Kettering Cancer Center in New York for lung cancer research.
Each gift followed a step of their own path. They funded the place they left in 1989, the department where they learned to build libraries of molecules, and a cancer hospital in the city where they had been students. The Columbia announcement quoted both of them. Li said the education "Ning and I received" had shaped "our passion for doing the right thing for patients." Zhao said she was "proud to support the students, faculty, and staff who are dedicated to excellence in chemical science." She was president of the Ge Li & Ning Zhao Family Foundation. Her statement named the dean who had advised them on their giving. It did not mention her illness.
One Chinese corporate database lists Li's current appointment as WuXi's chief executive as dated June 6, 2023, three weeks after her death. It is almost certainly routine board paperwork renewing a title he had held since the beginning. Still, the date stays with you.
The Penalty for Doing More
The American stock market gave WuXi a price, then a discount, and then a reason to leave.
The company listed on the New York Stock Exchange in 2007 under the ticker WX. Its filings from those years are full of small, legible facts. A Schedule 13G amendment filed for the period ending December 31, 2009, reports that Li beneficially owned 25,065,743 ordinary shares, 4.5 percent of the company. Of those, 3,300,580 were held directly, along with 1,279,010 American Depositary Shares, each representing eight ordinary shares. Another 9,179,291 ordinary shares and 94,890 ADSs sat in the NGM Family 2006 Irrevocable Trust, administered by J.P. Morgan Trust Company of Delaware. Row 4 of the form, Citizenship or Place of Organization, says: United States of America.
Four point five percent is a small stake for a founder. Li had diluted himself heavily to fund a business that ate capital: instruments, plants, acquisitions. He was building it inside a market structure that, as he saw it, punished exactly that kind of building.
In early March 2015 WuXi reported earnings. Li had prepared a slide with what he considered a simple message. "It said, this is our core business, and it's going to grow. The new business, we're going to invest." He expected the stock to rise, or at least hold. It fell 20 percent.
— Ge Li, interview with C&EN, February 24, 2016So I thought, this is terrible: The more we do, the more we are penalized. It's very disincentivizing to us to do something new. So I said, that's about the time to delist the company.
Five months later he had a plan in writing. On August 14, 2015, WuXi PharmaTech (Cayman) Inc. signed a merger agreement with New WuXi Life Science Limited, valuing the company at about $3.3 billion. The same day, a confidential equity commitment letter went to a Cayman Islands vehicle called Group & Cloud Limited, care of 288 Fute Zhong Road, "Attention: Ge Li." Its letterhead listed a fax number, +86-21-50463718, which is a reminder that in 2015 billion-dollar Chinese deals still assumed someone might send a fax. Under the letter Li committed at least $60 million of his own cash. Against that equity, Ping An Bank and Shanghai Pudong Development Bank committed to underwrite a management loan of up to $300 million. The founder put money into the structure himself, and the Chinese banks lent five times as much against it.
The 2016 interview contains what may be the most emphatic denial in Li's public record. Tremblay asked whether WuXi had left New York to relist on a Chinese exchange, where valuations were higher. Li answered: "No! No! It was absolutely not the reason. Not to arbitrage the value between the U.S. and China stock exchanges; no, that was totally not the reason." The headline on Tremblay's main story that week said the founder "claims no interest" in relisting in China.
The following April, Tremblay reported that WuXi was seeking a Chinese listing. In 2018 WuXi AppTec raised more than $900 million in a Shanghai IPO on fast-track approval, then listed in Hong Kong as well, with an initial valuation of $1 billion for that offering. WuXi was not unusual: other Chinese firms delisted from U.S. exchanges in 2015, according to the trade press, "in a bid to obtain higher valuations closer to home."
You can read this two ways, and the record allows both. A skeptic says that "No! No!" was untrue when he said it. A more generous reader says Li believed, sincerely and in the moment, that he was escaping Wall Street's short-termism rather than chasing Shanghai multiples, and that what he did afterward was simply the obvious next step, whatever he had felt about it. Both readings end the same way. WuXi left the American market for one it understood, and the company's trading home and capital moved from New York to Shanghai and Hong Kong.
He had his explanation for 2010 ready by then. Charles River, he said, had been meant to "put together some fully integrated capabilities, from discovery, early development, to development." The shareholders "didn't see the value." "But we went on to continue to build. And we've proven the value of this platform; we've proven the value of the vision." The market value, he noted, had gone from $1.6 billion to $3.3 billion. He said it the way a chemist reports a yield.
A Pencil, a Piece of Paper, and a Credit Card
The most-repeated thing Li has said in public was meant as an industry observation. Tremblay quoted it in 2016 as a fact about how drug companies get started now.
— Ge Li, quoted in C&EN, March 14, 2016A few decades ago, it was costly to start a pharmaceutical company... with a piece of paper, a pencil, and a credit card.
Investors once had to build laboratories and hire researchers before testing a single idea. With service providers like WuXi, Li said, an entrepreneur could start a drug company with almost nothing but a thesis and a payment method. He called running a company that lowered those barriers "totally inspiring," and the plainness of the phrase is convincing.
That same year he insisted that WuXi would never become what the money kept pushing it to become, a drug company with its own patented products. "From day one, I've said that WuXi is not going to become a pharmaceutical company. It's never been our aspiration." And: "Why would we break something that is doing very well to be another of the 6,000 pharmaceutical companies in China?" This time the actions matched the words. A decade on, WuXi still makes other companies' medicines. According to The New York Times, it produces a large share of the ingredients used in treatments for leukemia, lymphoma, HIV and obesity, sold under other companies' brand names.
The scale of the platform is easy to miss when it's presented as a list. In 2016 WuXi had about 10,000 employees, roughly 1,000 of them in the United States, 2,000 customers, 23 R&D sites, and annual sales running near $800 million, based on $213 million in the third quarter of 2015 before it went private. By 2019, when it won "CEO of the Year" at CPhI Worldwide, the company counted more than 3,700 customers and partners in more than 30 countries. By 2025 the numbers were 39,000 employees and about 6,000 customers. The capabilities grew outward from chemistry into nearly everything else: toxicology in Suzhou in 2009; large-scale manufacturing at Jinshan in 2010; biologics in Shanghai and Wuxi City in 2011; a chemistry facility in Wuhan in 2012; a new campus in Changzhou in 2016; an oligonucleotide plant there in 2020; a tablet and capsule plant in Switzerland bought from Bristol Myers Squibb in 2021.
As usual, Li handled the parts that grew faster than the parent by separating them. WuXi Biologics, which he had chaired since 2014, was spun off and listed in Hong Kong in June 2017, priced at the top of its range. In May 2017 he merged WuXi's venture arm with Frontline to create, in the trade press's phrase, an $800 million "trans-Pacific" biotech fund. Even the venture capital had to be described as straddling an ocean.
One subsidiary had to be given up. In 2015 WuXi had bought NextCODE Health, a bioinformatics start-up spun out in 2013 from deCODE genetics, the Icelandic company built on a nation's genomes. In 2019, "in response to new regulations in China," WuXi NextCODE was separated from its parent. It became Genuity Science and was bought by HiberCell, a New York biotech, in August 2021. It was a small transaction, but it was the first time a government's rules about data, not a client's demand or a shareholder's patience, forced the platform to drop a piece of itself. It foreshadowed what came later.
The company slogan, which Li repeated at forums and award ceremonies, was "every drug can be made and every disease can be treated." Opening a WuXi Healthcare Forum, he called the gathering "a forum that belongs to everyone in the global healthcare ecosystem." Everyone was the important word. The platform was meant to have no allegiance to any customer, any target, or any country.
Doing It Right
In June 2012 a blogger who signs herself Sofie, who works in biotech, says she "travels in the Chinese life science circle," and invests in stocks with her husband Michael, wrote a post titled "An Exceptional Leader." She explained, a little ruefully, that the biotech stock Michael had studied "in excruciating details," Dendreon, was their biggest unrealized loss, while the stock she had bought on instinct about its leader was the only big biotech position that had made them money. That stock was WuXi.
The occasion for the post was bad news. WuXi had just put out a press release disclosing that a former junior employee had been caught stealing compounds from a client company. For a business whose entire value proposition was that it could be trusted with clients' molecules, this was close to the worst story it could tell about itself, and the company told it before anyone forced it to. Sofie wrote that she "applaud[ed] their courage to put out a press release, take responsibility and not shy away." She emailed Li, flattering him "a little," as she admitted. He answered quickly and saw through her:
"thank you, my friend. I guess you are writing this email to show support for me and the company."
He went on, she reported, to say he always wanted to do the right thing even when it was difficult. Then he asked about her son, Winston.
It's a small exchange, and it shows something that rarely appears in his formal statements. Li read the motive behind the email, accepted the kindness without making a show of it, restated his principle, and then asked about her child. That is how a good client manager behaves. It is also how a decent man behaves. In this case there's no reason to think they were different.
The principle eventually became company doctrine. By 2024 WuXi described its core value as "doing the right thing and doing it right." The phrase works as an engineer's distinction: the first half is about choosing the right objective, the second about executing it correctly. It is the kind of slogan a chemist would write, separating what you are trying to make from whether you made it cleanly. Li used versions of it everywhere. At Columbia in 2020 it was "our passion for doing the right thing for patients."
In February 2024 the phrase appeared in a document no one at WuXi had expected to write.
Red Genes
In January 2024 members of the U.S. Congress introduced a bill called the BIOSECURE Act. It named WuXi AppTec, among others, as a biotechnology company of concern and aimed to bar it from federal contracts, citing ties to "a foreign adversary's military, internal security forces, or intelligence agencies." WuXi's shares fell when the bill appeared and kept falling.
On February 4, 2024, the company published an open letter to its customers signed by Ge Li, Ph.D., Chairman & CEO; Minzhang Chen, Ph.D., Co-CEO; and Steve Yang, Ph.D., Co-CEO. All three signatures carried doctorates, and the letter used the language of the lab, not of a lobbyist. It invoked "doing the right thing and doing it right." It called the claims "unfounded and misleading." It said the company welcomed regulatory oversight but objected "to blanket allegations and preemptive actions against our company without due process." And it made the central claim in one flat sentence:
— Open letter signed by Ge Li, Minzhang Chen and Steve Yang, February 4, 2024We want to be clear and set the record straight: WuXi AppTec does not pose a national security risk to any country.
To any country. That was the platform's neutrality, put in writing.
The escalation was quick, and each step had a date. Later that month the Jamestown Foundation, a Washington research institute focused on China, published an analysis titled "Red Genes: Assessing WuXi AppTec's Ties to the Party-Army-State in China," by Sunny Cheung, Arran Hope and Peter Mattis. It concluded that Li had "participated intensely in CCP activities for decades." It also said he had spoken publicly about "the central role of the Party in the WuXi Group's corporate activities as well as the role that WuXi Group plays in China achieving its national security and geostrategic science and technology objectives." On February 12, the chair and ranking member of the House Select Committee on the Chinese Communist Party joined Senators Gary Peters and Bill Hagerty in asking Treasury, Defense and Commerce to review WuXi AppTec and WuXi Biologics for sanctions. On March 19, the Financial Times reported that WuXi had started a lobbying campaign in the United States. On March 28, Reuters, citing two people familiar with a classified briefing for senators, reported that U.S. intelligence and diplomatic officials had said WuXi transferred a U.S. client's intellectual property to Chinese authorities without consent. WuXi denied any unauthorized transfer and said it complied with U.S. law.
That last allegation went to the foundation of the business. It was the same thing Li had warned about on the AmCham panel in 2005, when he said no WuXi would exist without strong IP protection. The whole enterprise rested on the promise that the Merck room's work stayed in the Merck room. A denial was the only answer available, and a denial cannot be as specific as a classified briefing.
The record supports two pictures of the same man, and it's dishonest to show only one. In one, Li is an American citizen, as Row 4 of the 13G says. He was elected in 2011 to the Committee of 100, an organization of prominent Chinese Americans. He gave $21.5 million to Columbia and $20 million to a cancer hospital in Manhattan. In 2021 Delaware approved $19 million in tax incentives for a WuXi division's planned plant in Middletown, under the code name "Project Dragonfly." In the other picture, on September 29, 2005, in the Great Hall of the People in Beijing, Li received the Distinguished Entrepreneur Award from the Overseas Chinese Affairs Office of the State Council. A Chinese corporate database's biography of him begins American nationality, has obtained the People's Republic of China foreigner's, and on the page I read the sentence then cuts off in an ellipsis.
Both pictures are true. For two decades the business worked because nobody required them to be reconciled.
That changed. The House passed BIOSECURE on September 9, 2024. In October the Financial Times reported that WuXi was considering selling its U.S. and European facilities because the bill was scaring off clients. In December 2024 it agreed to sell Oxford Genetics, the UK gene-therapy firm it had bought in 2021, together with WuXi Advanced Therapies, to an American private equity firm. In January 2025 it sold its U.S. medical-device testing operations, in Minnesota and Georgia, to a device-testing contract research company called NAMSA. The bill failed in the 2024 session, came back inside the National Defense Authorization Act for Fiscal Year 2026, and became law on December 18, 2025. In October 2025 the Pentagon said WuXi AppTec merited inclusion on its list of companies linked to China's military. In June 2026 it was added to the 1260H list.
Li's own disclosures had long described the company as an "open-access" platform, the library that doesn't care which compound wins. The 1260H list describes it in terms of which side it is on.
What the Name Kept
The company was not always called WuXi AppTec. Until 2008 it was WuXi PharmaTech, a name made from a Chinese city and two generic English syllables. Then, in early 2008, it bought AppTec Laboratory Services, an American company founded only in 2001, a year after WuXi. AppTec tested medical devices and biologics at laboratories in St. Paul, Minnesota; Philadelphia; and Atlanta. Li's company took its name. Afterward the name said what the business was: a Chinese chemistry platform combined with an American testing lab, two places in one brand.
The encyclopedia entry for the company explains how English speakers should say the first word: Wu-shee. It doesn't explain the second word, because no one has ever needed help with it.
In January 2025 the American testing labs in Minnesota and Georgia, in the states where AppTec had kept its sites when Li bought it, went to NAMSA. The people who had answered emails at the start of their day, while Shanghai answered at the end of its day, now worked for someone else.
On the Shanghai Stock Exchange, under 603259, and in Hong Kong, under 2359, the company is still called WuXi AppTec.
Part IIThe Playbook
The principles below are drawn from a career of operating in between: between disciplines, between capital markets, and between two governments that each came to regard the in-between position as suspect. Some are tactical, about free trade zones, take-private structures and the timing of disclosure. Others concern what a service business can and cannot promise. The final principle is a warning, not a recipe, because it describes how Li's strategy ended up under attack.
The Ge Li Playbook
- 1.Sell the shovels and refuse the gold.
- 2.Let the failed mission become the business plan.
- 3.Work on the customer's clock.
- 4.Treat regulatory geography as capital.
- 5.Make trust visible in the hallway.
- 6.Move downstream before you are asked.
- 7.Buy credibility your geography cannot grow.
- 8.When a buyer walks, build what they refused.
- 9.Choose your shareholders the way you choose your customers.
- 10.Put your own cash where the leverage begins.
- 11.Disclose the worst thing yourself.
- 12.Neutrality is a position someone else gets to define.
Principle 1
Sell the shovels and refuse the gold
The hardest discipline in Li's career has been not taking the obvious upside. By 2016 WuXi had seen more drug programs than almost any organization in the world, and investors kept assuming it would eventually launch its own patented drugs, collecting a share of the gold instead of renting out the tools. Li refused, repeatedly and in public: "Why would we break something that is doing very well to be another of the 6,000 pharmaceutical companies in China?"
The reason goes beyond modesty. A platform that competes with its customers stops being a platform. Every Merck project in the Waigaoqiao "R&D mall" relied on the assurance that WuXi did not want Merck's molecule for itself. Once WuXi had a pipeline of its own, every client would have to wonder what WuXi learned from its project. Refusing the gold is what made the shovels worth buying.
Li also gave an epistemological reason: "We don't have a crystal ball." Combinatorial training taught him that nobody predicts winners reliably. If you can't pick winners, the durable business is the one that gets paid on every attempt, as the shovel seller does.
Tactic: If your service business has privileged visibility into customers' bets, write down publicly and early which of those bets you will never make yourself, and keep to it when the upside gets large.
Principle 2
Let the failed mission become the business plan
WuXi came out of a joint venture that never happened. In 1999 Pharmacopeia sent Li to China to find a research partner. There wasn't one, because there was no pharmaceutical contract research industry in China. Li concluded that the gap was the opportunity. He titled his 2012 Peking University lecture "Being an Accidental Entrepreneur," but the accident was only the failure. Recognizing what it meant was deliberate.
The useful skill is to treat a failed assignment as information about the market. A corporate mission that fails because the partner doesn't exist is telling you the partner should exist. Most executives write up the failure and move on. Li quit and became the missing partner.
Tactic: After any failed partnership search, ask whether it failed because the counterparty was weak or because the counterparty doesn't exist yet, and treat the second answer as a possible company.
Principle 3
Work on the customer's clock
In 2004 Li told C&EN that his employees routinely stayed until 10 or 11 at night to talk with overseas clients during their working hours. Six years later his letter announcing the Charles River deal opened "Good afternoon and good morning." In both cases the company's working day was built around the client's timezone, not the founder's.
This mattered more than it seems. Offshore research was then mainly sold on cost, and cost advantages disappear once communication slows down. A Shanghai lab that answers questions overnight is cheap but costs the client a day per cycle. One that answers live, during the client's own meeting, is cheap and fast, and that combination is much harder to compete with. Li gave up his staff's evenings to remove the delay that would otherwise have offset the price advantage.
Tactic: If you serve customers across time zones, set at least part of your operating day to their working hours, so distance stops costing them a day.
Principle 4
Treat regulatory geography as capital
The Waigaoqiao Free Trade Zone was a balance-sheet decision. Inside it, Li told Tremblay, instruments and spare parts arrived tax-free, saving about $1.5 million on a $12 million investment, and lab chemicals arrived from abroad in about a week. For a business selling speed to foreign drug companies, customs efficiency was part of the product.
The less obvious point is that jurisdiction is something you can choose. Most founders take their regulatory environment as given. Li chose the specific zone within a city where import rules were most favorable to a business built on foreign inputs and foreign clients. Twenty years later the same habit shows up in the planned Singapore expansion and the Delaware plant. The capability stays the same; the address is chosen deliberately.
Tactic: Before choosing a site, model how many days of lead time the local import, tax and permitting rules will cost you on critical inputs, and price those days as capital.
Principle 5
Make trust visible in the hallway
Tremblay noticed the safety glasses, "a rare sight in China," and the emergency showers in the corridors. They cost little and they answered a question clients rarely asked out loud: will this lab work the way my lab works? A visiting scientist from Lilly or Merck could see the answer walking to the seminar room.
The broader lesson is that a service business entering a market with low expectations has to make its standards visible. Certifications help, but what people see in the building is more convincing because it's hard to fake every day. The Lilly researcher giving a seminar in WuXi's conference hall was also, in effect, inspecting the place.
Tactic: List the three things a skeptical client's scientist would look for when walking through your operation, and make sure all three are plainly visible on any given day, not only on audit day.
Principle 6
Move downstream before you are asked
In 2004 WuXi was making milligram and gram quantities of compounds for discovery chemistry. It had already spent $6 million on a GMP-certified plant in Jinshan to make kilograms or tons of active pharmaceutical ingredients for clinical trials. The logic was simple: a compound that works in discovery has to be made in larger quantities next, and the lab that first made it understands its chemistry best.
That progression continued for twenty years: toxicology, biologics, clinical services, cell and gene therapy, commercial manufacturing. Each step followed a client's molecule one stage further. Li's 2010 description of the Charles River thesis, "fully integrated capabilities, from discovery, early development, to development," described what he had been doing since 2004.
Tactic: Map the next stage your customers' work goes to after it leaves you, and start building that capability before they ask, while you are still the obvious supplier.
Principle 7
Buy credibility your geography cannot grow
WuXi's acquisitions show a pattern. A Chinese company that wants Western regulated work needs Western-regulated facilities and Western reputations, and those are slow or impossible to build from Shanghai. Li bought them.
W
What WuXi Bought, and What Became of It
Acquisitions as purchases of capability and credibility. Several were later sold under political pressure.
| Year | Acquisition | What it brought | Status |
|---|---|---|---|
| 2008 | AppTec Laboratory Services | U.S. device and biologics testing; St. Paul, Philadelphia, Atlanta; and the company's new name | Device testing sold to NAMSA, 2025 |
| 2011 | Abgent (San Diego) | Antibody reagents for research and discovery | Capability added |
| 2014 | XenoBiotic Laboratories | 27 years of bioanalytical and DMPK history | Capability added |
| 2015 | NextCODE Health | Genomic bioinformatics, out of Iceland's deCODE | Separated 2019 after Chinese rules |
| 2016 | Crelux GmbH (Munich) | Structure-based drug discovery | Capability added |
| 2021 | Oxgene (UK) | Cell and gene therapy tools | Sale announced December 2024 |
| 2021 | BMS plant (Switzerland) | Tablet and capsule manufacturing | Western manufacturing footprint |
The AppTec deal stands out. Li bought a seven-year-old American company and renamed his own firm after it. The name signaled to Western clients that this was partly an American operation, and it was. The column on the right shows what happened later: credibility bought in one jurisdiction is held at that jurisdiction's discretion.
Tactic: When an acquisition is mainly a purchase of credibility, assume the credibility can be taken back by the government that granted it, and structure the deal so the business survives if you have to sell that piece.
Principle 8
When a buyer walks, build what they refused
Charles River agreed to pay $1.6 billion for WuXi in April 2010. Its shareholders refused. Li publicly blamed "short-term financial concerns" and then spent five years building on his own the integrated discovery-to-development platform the merger was supposed to create. By 2015 the take-private valued the company at about $3.3 billion. "We've proven the value of this platform," he said later. "We've proven the value of the vision."
A failed acquisition usually shows you which part of your story the buyer valued. Charles River's management valued integration. Its shareholders valued safety, and by one account considered the premium too high "for a Chinese company." Li took the first view as confirmation and the second as a bias he would outlast, which he did.
Tactic: When a deal collapses, write down the strategic thesis the buyer's management accepted, separately from the reasons its shareholders rejected it, and fund the thesis yourself if you still believe it.
Li's account of the 2015 delisting is a lesson in shareholder fit. He told the market WuXi would invest in new businesses alongside a growing core. The stock fell 20 percent. "The more we do, the more we are penalized." A company whose strategy is to keep building capacity can't function with a shareholder base that penalizes building capacity.
$
The Capital Path
From New York to Shanghai and Hong Kong, with each move tied to a specific frustration or opportunity.
2007
IPO on the New York Stock Exchange under the ticker WX.
2010
Charles River agrees to pay $1.6 billion; its shareholders block the deal.
2015
Shares fall 20% after March earnings. On August 14, Li signs a merger agreement to take the company private at about $3.3 billion.
2016
Li tells C&EN that relisting in China was "absolutely not the reason."
2017
WuXi Biologics spun off and listed in Hong Kong.
2018
WuXi AppTec raises more than $900 million in a Shanghai IPO, then lists in Hong Kong.
2025
BIOSECURE becomes law on December 18 inside the FY2026 defense authorization.
The cautionary note is the "No! No!" Li denied, emphatically and on the record, a move he made two years later. Whatever he meant at the time, the record now contradicts the quote. Founders who rearrange their capital structure should avoid ruling out options in public that they may later need.
Tactic: Before listing, test whether the market's typical holder will reward or punish your next three years of planned investment, and avoid public denials about future listings you can't guarantee.
Principle 10
Put your own cash where the leverage begins
The 2015 equity commitment letter is short. Li agreed to contribute at least $60 million to Group & Cloud Limited, a Cayman vehicle. In return Ping An Bank and Shanghai Pudong Development Bank agreed to underwrite up to $300 million in management debt. The founder's equity was the condition on which the banks' lending depended.
The arrangement was unusual for a founder who in 2009 owned only 4.5 percent of the company. Li used a relatively modest personal commitment to raise about five times as much from lenders, and the structure made clear to everyone that he bore the first losses. A founder whose own money is in the first-loss position makes a credible borrower.
Tactic: In any leveraged transaction you lead, commit your own capital to the first-loss position and let lenders see the size of that commitment.
Principle 11
Disclose the worst thing yourself
In 2012 a former junior WuXi employee was caught stealing compounds from a client. For a company selling confidentiality, it was close to the worst possible story. WuXi issued its own press release. At least one investor in the industry, the blogger Sofie, wrote that it increased her confidence: she "applaud[ed] their courage to put out a press release, take responsibility and not shy away."
The logic is about who controls the story. A breach disclosed by the company comes across as integrity. The same breach found by a client or a regulator comes across as a cover-up. Li applied the principle in his reply to Sofie, restating that he wanted to do the right thing "even if it's difficult." The 2024 crisis shows the limit: when the allegation comes from a classified briefing, the company can't disclose first, because it is never told the specifics.
Tactic: Write the disclosure protocol for your worst plausible breach before it happens, with a fixed number of hours between discovery and public statement.
Principle 12
Neutrality is a position someone else gets to define
For two decades Li's strategy depended on being a platform with no side: open-access, "a forum that belongs to everyone," a library that doesn't care which compound wins. The 2024 open letter put it in a single line: WuXi "does not pose a national security risk to any country."
But a platform's neutrality is decided by the governments of the places it operates, not by the platform. Beijing's 2019 rules took NextCODE away. Washington's BIOSECURE Act, the Pentagon's October 2025 determination and the 1260H listing in June 2026 forced the sale of the Minnesota and Georgia labs, Oxgene and WuXi Advanced Therapies. The Jamestown analysis described Li's relationship with the Party in terms the company rejects. The rejection doesn't settle the matter, because it isn't WuXi's to settle.
!
The Two Records
Both are documented. For twenty years nobody required them to be reconciled.
| The American record | The Chinese record |
|---|---|
| U.S. citizenship listed on SEC Schedule 13G | Distinguished Entrepreneur Award, Great Hall of the People, September 29, 2005 |
| Committee of 100 member, 2011 | Jamestown: "participated intensely in CCP activities for decades" |
| $21.5M to Columbia, $20M to Memorial Sloan Kettering | 100M RMB to Peking University; honorary trustee |
| $19M Delaware incentives for "Project Dragonfly" | Company relisted in Shanghai and Hong Kong, 2018 |
Tactic: Rank your critical assets by which government could force you to sell them, and decide before any crisis which ones you could separate cleanly.
Free playbook
Get The Business Model Playbook
58 business models, one visual page each: how the money flows, the metrics that matter, and who runs it. Free when you join the Faster Than Normal email.
Free. No spam. Unsubscribe anytime.
Part IIIQuotes and Maxims
In their words
— Ge Li, interview with C&EN, February 24, 2016From day one, I've said that WuXi is not going to become a pharmaceutical company. It's never been our aspiration. We want to be a platform of technology, science, and capabilities to enable anyone to discover a new health care product to benefit patients.
— Ge Li, interview with C&EN, February 24, 2016Drug discovery and development is not as simple as you think. You think we gain knowledge and know what to make, or what will be successful, but it's not really that way. For example, everyone goes to one target, but it doesn't mean that this target will necessarily work. We know the popularity. But we don't really know if it's going to work.
— Ge Li, opening the WuXi Healthcare ForumThis is a forum that belongs to everyone in the global healthcare ecosystem. It is a platform of knowledge, wisdom, and learning to provide the key points to success, and just as crucially, the lessons we can learn from failures of the past.
— Ge Li, on the $21.5 million gift to Columbia University, July 28, 2020The exceptional education that Ning and I received as students at Columbia University has played an important role in our career and in fostering our passion for doing the right thing for patients.
— Ge Li, in an email quoted on Sofie's Blog, June 7, 2012thank you, my friend. I guess you are writing this email to show support for me and the company.
Maxims
- Sell the shovels. A platform that competes with its customers loses its customers' trust.
- Distrust the crystal ball. If no one can predict which bet wins, build the capacity to run all the bets.
- Read a failed mission as a market. If the partner you were sent to find doesn't exist, consider becoming that partner.
- Work on the client's clock. Low cost only helps if slow communication doesn't eat the savings.
- Choose your jurisdiction. A tax-free import and a one-week shipping time are capital you can plan around.
- Make standards visible. Safety glasses in the corridor persuade visitors more than certificates on the wall.
- Build what the buyer refused. A collapsed deal tells you which part of your thesis was right.
- Pick shareholders who reward building. If investors penalize you for building, change the investors before you change the plan.
- Disclose first. A breach you announce reads as integrity; one someone else finds reads as a cover-up.
- Expect your neutrality to be challenged. You can claim the space between two countries, but governments on either side decide whether you get to keep it.
